FSFatih Selcukbiricik

Fatih Selcukbiricik

*This is an algorithmically generated author record based on publicly available information.

Fatih Selcukbiricik has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours—results from a Turkish multi-centre study

    by Omer Fatih Olmez, Ahmet Bilici, Ozlem Er, Atil Bisgin, Alper Sevinc, Tulay Akman, Ruchan Uslu, Nil Molinas Mandel, Suayib Yalcin, Mehmet Teomete, et al.

    The objective of this multi-centre, real-world study was to examine the potential influence of comprehensive molecular profiling on the development of treatment decisions or adjustments for patients with advanced solid malignancies. We then evaluated the impact of these informed choices on patient treatment outcomes. The study encompassed 234 adult patients (mean age: 52.7 ± 14.3 years, 54.7% women) who were diagnosed with solid tumours at 21 different medical centres in Turkey. Remarkably, 67.9% of the patients exhibited metastasis at the time of diagnosis. We utilized an OncoDNA (Gosselies, Belgium) platform (OncoDEEP) integrating next-generation sequencing with additional tests to harvest complex molecular profiling data. The results were analyzed in relation with two specific outcomes: (i) the impact on therapeutic decisions, including formulation or modifications, and (ii) associated treatment response. Out of the 228 patients with final molecular profiling results, 118 (50.4%) had their treatment modified, whilst the remaining 110 (47.0%) did not. The response rates were comparable, with 3.9 versus 3.4% for complete response, 13.6 versus 29.3% for partial response, 66.9 versus 51.7% for progressive disease and 15.5 versus 15.5% for stable disease for treatments informed and not informed by complex molecular profiling, respectively (P = 0.16). Our real-world findings highlight the significant impact of complex molecular profiling on the treatment decisions made by oncologists for a substantial portion of patients with advanced solid tumours. Regrettably, no significant advantage was detected in terms of treatment response or disease control rates.


  • Outcomes of surveillance VS. adjuvant chemotherapy for patients with STAGE IA and IB NON-seminomatous testicular germ-cell tumors.

    by Ahmet Bilici, Mahmut Gumus, Hatice Odabas, Nurten Kandemir, Umut Demirci, Sener Cihan, Ibrahim Vedat Bayoglu, Bala Basak Oven Ustaalioglu, Turkan Ozturk, Esma Turkmen, et al.

    E16051 Background: Approximately 50-60% of nonseminomatous germ-cell tumors (NSGCT) present with clinical stage I (CS I). Initial active surveillance, adjuvant chemotherapy and retroperitoneal lymph node dissection (RPLND) are acceptable three treatment options for these patients, but there is no uniform consensus. In this study, outcomes of active surveillance and adjuvant chemotherapy were compared in CS I NSGCT. Methods: A total of 201 patients with CS I NSGCT after orchiectomy in Turkey were included. Outcomes of active surveillance and adjuvant chemotherapy were retrospectively analyzed. The prognostic factors and the factors predicting relapse were evaluated. Results: Of the 201 patients, 110 (54.7) received adjuvant chemotherapy, while the remaining 91 patients (45.3%) underwent surveillance. Relapses were significantly higher for patients underwent surveillance compared to adjuvant chemotherapy group (18.3% vs. 1.2%, p < 0.001). The five-year disease-free survival (DFS) rate for patients who were treated with adjuvant chemotherapy were significantly better than surveillance group (97.6% vs. 80.8%, respectively; p < 0.001), but overall survival (OS) rates were similar. Univariate analysis showed that the presence of vascular invasion and treatment option for DFS and pT stage, invasion of rete testis, and the presence of relapse for OS were significant prognostic factors. Multivariate analysis revealed that the treatment strategy was an independent prognostic factor for DFS (p < 0.001). A logistic regression analysis demonstrated that treatment options (p = 0.031), EC > %50 (p = 0.013) and tumor diameter (p = 0.016) were found to be an independent factor for predicting relapse. Conclusions: Our results indicate that adjuvant chemotherapy is associated with improved DFS compared with surveillance for CS I NSGCT. The treatment strategy is an important prognostic indicator for DFS and a predictive factor for relapse. Although adjuvant chemotherapy seems to be a suitable treatment for patients with risk factors for relapse, surveillance is still feasible management option. More reliable predictive factors are needed to make treatment decisions.

    • 29 April 2015
      • Vol. 62  (137) , 59-64

    Is perineural invasion (PN) a determinant of disease free survival in early stage colorectal cancer?

    by Mehmet Akif Ozturk, Faysal Dane, Sila Karagoz, Deniz Tural, Fatih Selcukbiricik, Fuat Demirelli, Evin Buyukunal, Mustafa Ozguroglu, Hande Turna, Sibel Erdamar, et al.

    The prognostic importance of perineural invasion (PN) in colorectal cancer (CRC) is unclear. The aim of this study to find out whether the PN was an independent stratification factor of postoperative relapse in curatively resected high-risk stage II & III CRC patients who were treated with adjuvant therapy. Data of patients with high risk stage II & all stage III CRCs treated with adjuvant chemotherapy were retrospectively analyzed. Pathological features of final surgical specimen were noted. Disease-free survival was determined by Kaplan-Meier estimator, with differences determined by multivariate analysis using the Cox multiple hazards model. Results were compared using the log-rank test. PN was found to be positive in 26% in the files of 593 eligible patients. In 21% of the reports PN status was not reported. Presence of PN in the resected primary tumors did not have independent effect on DFS. Further analyses for importance of PN on DFS of colon or rectal cancers did not show any effect. This study had failed to demonstrate any prognostic effect of PN for DFS in surgically resected stage II and III CRC patients who received adjuvant treatments.

    • 1 September 2013
      • Vol. 60  (126) , 1365-70

    The relation between pathological complete response and clinical outcome in patients with rectal cancer.

    by Deniz Tural, Fatih Selcukbiricik, Mehmet Akif Özturk, Ozcan Yildiz, Hande Turna, Sibel Erdamar, Evin Büyükünal, Süheyla Serdengeçti

    Preoperative chemoradiotherapy (CRT) is the standard treatment modality in locally advanced rectal cancer. The primary aim was to correlate pathological complete response (pCR) with patient outcome, and the secondary objective was to identify predictive factors of pCR. Patients with clinical stage II/III rectal cancer who received preoperative CRT between 2002 and 2010 were retrospectively studied.The median radiotherapy dose was 54 Gy (range, 45 to 64 Gy), and all patients received concurrent infusional 5-fluorouracil-based chemotherapy. Median follow-up time was 48.3 months (range, 24 to 96 months) and 51 months (range, 44 to 110 months) for no-pCR and pCR groups, respectively. Eighteen patients (18.6%) had pCR. The 5-year overall survival was 95% for patients with pCR and 74.8% in patients without pCR (p=0.009). The 5-year local relapse free survival was 87.5% and 95% for the no-pCR and pCR groups, respectively (p=0.09). The 5-year distant relapse free survival was 93% in pCR group and 79.8% in no-pCR group (p=0.02). The 5-year distant free survival was 94% and 66% in patients with and without pCR, respectively (p=0.017). The clinical T4 (p=0.043) and pretreatment carcinoembryonic antigen level (CEA) >5ng/mL (p=0.012) were significantly associated with a lower pCR rate. In the multivariate logistic regression analysis, pretreatment CEA level >5ng/mL (p=0.008) was the only independent factor associated with a lower pCR rate. Patients with pCR after preoperative CRT had a significantly improved outcome. Furthermore, the pretreatment CEA level was independently associated with pCR.


    • 25 April 2013
      • Vol. 18  (1) , 116-23

    The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.

    by F Selcukbiricik, S Erdamar, C U Ozkurt, N Molinas Mandel, F Demirelli, M Ozguroglu, D Tural, E Buyukunal, S Serdengecti

    Unlike cetuximab, there is a paucity of biomarkers for bevacizumab as predictors of outcome in metastatic colorectal cancer (mCRC) patients. Obviously exploring the worth of some potential markers in this setting is warranted. The purpose of this study was to investigate the predictive value of the presence of K-RAS and B-RAF mutations on the outcome of patients with mCRC treated with FOLFIRI and bevacizumab combination therapy. A total of 172 patients with mCRC were evaluated. K-RAS and B-RAF mutations were analyzed by quantitative PCR. Median progression-free survival (PFS) and overall survival (OS) were compared utilizing chi-square and Mann-Whitney U tests, respectively. Forty-four percent (N=77) of the patients were found to harbor K-RAS mutations and 6 (7.5%) were positive for B-RAF mutations. In baseline no difference in PFS and OS was observed between the groups with or without K-RAS mutation. No relationship was established between K-RAS and B-RAF mutation status and baseline CEA and CA19-9 tumor markers levels. K-RAS and B-RAF mutations do not seem to be predictive of treatment outcome as potential biomarkers for bevacizumab therapy in mCRC. However, not only the presence of K-RAS and B-RAF mutations but also the different biological behavior of the various subtypes of mutations should be considered as potential determinants in the final outcome of this disease.


  • The relation between pathologic complete response and clinical outcome in patients with rectal cancer.

    by Deniz Tural, Fatih Selcukbiricik, Mehmet Akif Dztfcrk, Dzcan Yildiz, Hande Turna, Sibel Erdamar, Evin Bfcyfckfcnal And


  • Association KRAS G13D tumor mutated outcome in patients with chemotherapy refractory metastatic colorectal cancer treated with cetuximab.

    by Deniz Tural, Fatih Selcukbiricik, Sibel Erdamar, Canan Unlu Ozkurt, Teoman Yanmaz, Nil Molinas Mandel, Süheyla Serdengeçti

    Cetuximab is currently approved for the treatment of metastatic colorectal cancer (mCR) with KRAS wild-type. Prior few studies demonstrated that G13D mutated tumors could benefit from cetuximab. This study aims to investigate whether KRAS G13D mutated tumors benefit from cetuximab in the chemotherapy refractory patients. We retrospectively compared progression-free survival (PFS), overall survival (OS) and response rate (RR) according to KRAS mutation status in 105 patients with mRC treated at the Cerrahpasa Medical School Hospital, between October 2008 and October 2011, with cetuximab alone or in combination with chemotherapy. PFS was significantly longer in patients G13D mutated tumors (6.81 months) than in patients with other KRAS mutated tumors (5 months) (p=0.027). No significant difference in PFS between patients G13D mutated and KRAS wild-type tumors was detected. No significant difference in OS was detected in patients between G13D mutated tumors and other KRAS mutated tumors. However, patients with KRAS wild-type tumors had significantly longer OS (16.1 months) than patients with mutated tumors (8.9 months) (p=0.025). RR in patients with other KRAS mutated tumors, was significantly worse than those with G13D mutated tumors (p=0.002). Our study demonstrated an association between the presence KRAS G13D mutanted and survival chemotherapy in refractory metastatic colorectal cancer treated with cetuximab.


  • Open Access

    Clinicopathological Features and Localization of Gastric Cancers and their Effects on Survival in Turkey

    by Fatih Selcukbiricik, Deniz Tural, Ahmet Bilici, Esengul Kocak Uzel, Mustafa Ozguroglu, Fuat Demirelli, Evin Buyukunal, Suheyla Serdengecti

    Clinicopathological Features and Localization of Gastric Cancers and their Effects on Survival in Turkey Gastric cancer;localization;proximal;treatment choices; Background: This study was designed to examine changing trends in localization of gastric cancer in Turkey in recent years. Materials and Methods: A total of 796 adult patients with newly diagnosed, histologically proven adenocarcinomas, treated and followed up at our oncology center between 2000-2011, were examined retrospectively. In all cases tumor localization were identified and recorded with clinicopathological features. Results: The median age was 58 with a range between 22-90 for the 552 men and 244 women. Median follow up was 12 months (1-276) and median overall survival was also 12 months (11.5-12.4). There was a trend for a change in tumor localization from distal to proximal. Survival of patients was low with advanced T and N stage tumours. Positive surgical margins, lymphovascular invasion, perineural invasion, cardioesophageal localization were predisposition factors for metastatic disease in gastric cancer. There was no relation between age or sex and histopathological type of gastric cancer. Conclusions: There is a trend in our country for a change in gastric tumour localization from distal to proximal, with clear significance for treatment choices.


  • Gastrointestinal Stromal Tumors in Turkey: Experiences from 3 Centers

    by Fatih Selcukbiricik, Suayip Yalçın, Deniz Tural, Sibel Erdamar, Gokhan Demir, Gülen Doğusoy, Nil Molinas Mandel

    Background: Gastrointestinal stromal tumors (GIST) are rare tumors of the gastrointestinal system. The most common primary site of GIST is the stomach. The treatment is primarily surgery, and the standard medical therapy is imatinib. Long-term survival can be obtained with good follow-up and treatment. Materials and Methods: In this study, data entry was performed using a web-based patient registry system for patients who were referred to 3 centers and retrospectively were diagnosed with GIST. Results: The study cohort consisted of 249 patients, including 160 men (64.3%) and 89 women (35.7%). The mean age was 59 years (range 21–90 years). Initially, 69.9% of the patients had local disease, while 30.1% had metastatic disease. The tumor was located in the stomach in 45.6% of patients. According to the Fletcher risk classification, the very low risk group included 8 subjects (3.2%), the low risk group included 40 subjects (16.1%), the moderate risk group included 56 subjects (22.5%), and the high risk group included 117 subjects (47%); the unspecified group included 28 subjects (11.5%). Conclusion: These data are important for revealing the clinicopathologic characteristics and survival data of patients with GIST, who are treated and followed up in Turkey.


  • Open Access

    Squamous Cell Carcinoma Arising in a Mature Cystic Teratoma

    by Suna Avcı, Fatih Selcukbiricik, Ahmet Bilici, Gülkan Özkan, Ayse Ayşim Özağarı, Fatih Borlu

    Introduction. Malignant transformation in a mature cystic teratoma of the ovary is a rare complication. Squamous cell carcinoma is the most common transformation. We describe a new case of squamous cell carcinoma arising in a mature cystic teratoma.Case Report. A premenopausal 52-year-old female patient is diagnosed with vaginal bleeding. According to examination made on the women and the pelvic scanning, 7 cm mass is found on the right adnexa of the patient. Total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, pelvic lymph node dissection, and debulking were the treatments completed on the patient. According to histopathological diagnosis, squamous cell carcinoma arising in a mature cystic teratoma is diagnosed as a reason for the mass in the right adnexa of the patient.Conclusion. The prognosis of the malign transformation of MCT depends on surgery stage; however it is extremely poor. The patient should receive chemotherapy regardless of stage. We have decided to administer second cycle carboplatin and paclitaxel treatments on the patient.